ČEŠKOVÁ, Eva. Practical issues in the treatment of schizophrenia. Minerva Psichiatrica. Edizioni Minerva Medica S.p.A., 2013, roč. 54, č. 2, s. 101-113. ISSN 0391-1772.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Practical issues in the treatment of schizophrenia
Autoři ČEŠKOVÁ, Eva (203 Česká republika, garant, domácí).
Vydání Minerva Psichiatrica, Edizioni Minerva Medica S.p.A. 2013, 0391-1772.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30000 3. Medical and Health Sciences
Stát vydavatele Itálie
Utajení není předmětem státního či obchodního tajemství
WWW URL
Kód RIV RIV/00216224:14740/13:00071043
Organizační jednotka Středoevropský technologický institut
Klíčová slova anglicky Evidence-based medicine; Individualized medicine; Schizophrenia
Štítky ok, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Olga Křížová, učo 56639. Změněno: 16. 1. 2014 08:50.
Anotace
Treatment should be evidence-based, measurement-based, complex (including pharmacotherapy, psychosocial intervention, and physical health care) and individualized (tailored to the patient). The basis of schizophrenia treatment is still pharmacotherapy. The first generation of antipsychotics (FGAs), known as typical APs, was discovered in the 1950s. Most second generation antipsychotics (SGAs), known as atypical APs, have been developed more recently. SGAs present some advantages in the treatment of certain treatment domains. The binding affinity of APs for specific neuroreceptors is associated with the therapeutic effect, but also with adverse events. The choice of AP for the individual patient should be guided by the side effect profile of the drug, patient experience with certain side effects, previous patient response to certain APs (e.g., individualized treatment), and potential interactions with other prescribed medication. There are some special clinical features influencing the choice of AP treatment (negative, cognitive, depressive and catatonic symptoms, agitation, non-adherence, pharmacoresistance). These features are discussed in more details. In the future more targeted therapies will be available, offering and enhance efficacy and hopefully also safety.
Návaznosti
ED1.1.00/02.0068, projekt VaVNázev: CEITEC - central european institute of technology
VytisknoutZobrazeno: 27. 7. 2024 14:06